194484-87-2

Upstream product

• 194484-86-1 (S)-1-[(S)-2-((S)-2-Benzyloxycarbonylamino-3-tert-butoxycarbonyl-propionylamino)-6-tert-butoxycarbonylamino-hexanoyl]-pyrrolidine-2-carboxylic acid 
• 90826-23-6 N-(N²-benzyloxycarbonyl-N⁶-tert-butoxycarbonyl-L-lysyl)-L-proline benzyl ester 
• 41446-22-4 (S)-3-Benzyloxycarbonylamino-4-isobutoxycarbonyloxy-4-oxo-butyric acid tert-butyl ester 
• 4583-24-8 H-Lys(Boc)-Pro-OH 
• 5545-52-8 Z-D(tBu)-OH 
• 2389-60-8 Z-Lys(Boc)-OH 

Downstream Products

• 194484-91-8 (S)-3-((S)-2-Benzyloxycarbonylamino-3-hydroxy-propionylamino)-N-[(S)-5-tert-butoxycarbonylamino-1-((S)-2-carbamoyl-pyrrolidine-1-carbonyl)-pentyl]-succinamic acid tert-butyl ester 

Relevant academic research and scientific papers

NAcSDKP analogues resistant to angiotensin-converting enzyme

Two series of analogues of the tetrapeptide NAcSDKP, an inhibitor of hematopoietic stem cell proliferation, were prepared, and their enzymatic stability toward rabbit lung angiotensin-converting enzyme (ACE) was evaluated as well as their capacity to inhibit NAcSDKP hydrolysis by this enzyme. In the first series, each of the peptide bonds has been successively replaced by an aminomethylene bond. In the second one, the C-terminus of the peptide has been modified by decarboxylation or amidation. The results reported here indicate that all of these molecules but one have good stability toward the enzyme but none of the compounds is able to inhibit NAcSDKP hydrolysis by ACE.